Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL

Clinical trial NCT06503263 · RECRUITING

Trial details

NCT number: NCT06503263
Sponsor: Navy General Hospital, Beijing
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-cell Lymphoma

Start date: 2024-08-30
Primary completion: 2030-07-30
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.